In Sum
Overall, the three-year results of these patients from the STOP-JIA study demonstrate that early combination treatment increases the duration of time patients spend in inactive disease. The early introduction of biologic DMARDs may increase the likelihood of achieving rapid improvement and maintaining clinically inactive disease for most patients with pJIA. These improved outcomes may meaningfully reduce overall disease damage and the long-term burden of disease.
For complete details, including source material, refer to the full study.
Excerpted and adapted from:
Ringold S, Ong MS, Tomlinson G, et al. Three-year outcomes and latent class trajectory analysis of the childhood arthritis and rheumatology research alliance polyarticular JIA consensus treatment plans study. Arthritis Rheumatol. 2025 Oct;77(10):1433–1441.
